Myelodysplastic syndrome, acute leukemia PNH after immunosuppressive therapy for severe aplastic anemia

摘要

Summary: Recent progress in the treatment of aplastic anemia (AA) has dramatically changed the previously grim prognosis for these patients. Improvements in immunosuppressive therapy have increase the number of long-term survivors so that immediate survival is no longer the sole concern. Here, we review the major clinical studies and summarize recent analyses of risk factors for developing paroxysmal nocturnal hemoglobinuria (PNH), myelodyplastic syndrome (MDS), and acute leukemia after treatment for aplastic anemia. We also review biological clues that may shed some light on the interrelationship between AA and clonal diseases.